Reversible anti-settlement activity against Amphibalanus (= Balanus ) amphitrite, Bugula neritina , and Hydroides elegans by a nontoxic pharmaceutical compound, mizolastine

Handle URI:
http://hdl.handle.net/10754/599506
Title:
Reversible anti-settlement activity against Amphibalanus (= Balanus ) amphitrite, Bugula neritina , and Hydroides elegans by a nontoxic pharmaceutical compound, mizolastine
Authors:
Zhou, Xiaojian; Xu, Ying; Jin, Cuili; Qian, Pei-Yuan
Abstract:
Mizolastine, an antihistamine pharmaceutical, was found to significantly inhibit larval settlement of the barnacle Amphibalanus (=Balanus) amphitrite, the bryozoan Bugula neritina, and the polychaete Hydroides elegans with EC50 values of 4.2, 11.2, and 4.1 mg ml-1, respectively. No toxicity against the larvae of these three species was observed at the concentration range tested during incubations with mizolastine. To determine whether the anti-settlement activity of mizolastine is reversible, recovery bioassays using these three species were conducted. More than 70% of the larvae that had been exposed for 4 h to mizolastine at concentrations four-fold greater than their respective EC50 values completed normal metamorphosis. The results of the recovery bioassay provide evidence that the antisettlement effect of mizolastine is reversible in addition to being nontoxic. The anti-settlement activities of several intermediates of the synthesis process of mizolastine were also examined. One of the intermediates, 2-chloro-1-(4- fluorobenzyl)-1H-benzo[d]imidazole, inhibited larval settlement and metamorphosis with low toxicity. These results may improve the understanding of the key functional group responsible for the anti-settlement activity of mizolastine. © 2009 Taylor & Francis.
Citation:
Zhou X, Xu Y, Jin C, Qian P-Y (2009) Reversible anti-settlement activity against Amphibalanus (= Balanus ) amphitrite, Bugula neritina , and Hydroides elegans by a nontoxic pharmaceutical compound, mizolastine . Biofouling 25: 739–747. Available: http://dx.doi.org/10.1080/08927010903154724.
Publisher:
Informa UK Limited
Journal:
Biofouling
KAUST Grant Number:
KAUST005-CML.07/08
Issue Date:
Nov-2009
DOI:
10.1080/08927010903154724
PubMed ID:
20183132
Type:
Article
ISSN:
0892-7014; 1029-2454
Sponsors:
This study was supported by a grant from the Chinese Ocean Mineral Resources Research and Development Association (COMAR06/07.SC02), and the CAS/SAFEA International Partnership Program for Creative Research Teams as well as a research fund from KAUST International Partnership Program (KAUST005-CML.07/08) to Qian P.-Y.
Appears in Collections:
Publications Acknowledging KAUST Support

Full metadata record

DC FieldValue Language
dc.contributor.authorZhou, Xiaojianen
dc.contributor.authorXu, Yingen
dc.contributor.authorJin, Cuilien
dc.contributor.authorQian, Pei-Yuanen
dc.date.accessioned2016-02-28T05:52:25Zen
dc.date.available2016-02-28T05:52:25Zen
dc.date.issued2009-11en
dc.identifier.citationZhou X, Xu Y, Jin C, Qian P-Y (2009) Reversible anti-settlement activity against Amphibalanus (= Balanus ) amphitrite, Bugula neritina , and Hydroides elegans by a nontoxic pharmaceutical compound, mizolastine . Biofouling 25: 739–747. Available: http://dx.doi.org/10.1080/08927010903154724.en
dc.identifier.issn0892-7014en
dc.identifier.issn1029-2454en
dc.identifier.pmid20183132en
dc.identifier.doi10.1080/08927010903154724en
dc.identifier.urihttp://hdl.handle.net/10754/599506en
dc.description.abstractMizolastine, an antihistamine pharmaceutical, was found to significantly inhibit larval settlement of the barnacle Amphibalanus (=Balanus) amphitrite, the bryozoan Bugula neritina, and the polychaete Hydroides elegans with EC50 values of 4.2, 11.2, and 4.1 mg ml-1, respectively. No toxicity against the larvae of these three species was observed at the concentration range tested during incubations with mizolastine. To determine whether the anti-settlement activity of mizolastine is reversible, recovery bioassays using these three species were conducted. More than 70% of the larvae that had been exposed for 4 h to mizolastine at concentrations four-fold greater than their respective EC50 values completed normal metamorphosis. The results of the recovery bioassay provide evidence that the antisettlement effect of mizolastine is reversible in addition to being nontoxic. The anti-settlement activities of several intermediates of the synthesis process of mizolastine were also examined. One of the intermediates, 2-chloro-1-(4- fluorobenzyl)-1H-benzo[d]imidazole, inhibited larval settlement and metamorphosis with low toxicity. These results may improve the understanding of the key functional group responsible for the anti-settlement activity of mizolastine. © 2009 Taylor & Francis.en
dc.description.sponsorshipThis study was supported by a grant from the Chinese Ocean Mineral Resources Research and Development Association (COMAR06/07.SC02), and the CAS/SAFEA International Partnership Program for Creative Research Teams as well as a research fund from KAUST International Partnership Program (KAUST005-CML.07/08) to Qian P.-Y.en
dc.publisherInforma UK Limiteden
dc.subjectAmphibalanus (=Balanus) amphitriteen
dc.subjectAnti-settlement activityen
dc.subjectBugula neritinaen
dc.subjectHydroides elegansen
dc.subjectLarvaeen
dc.subjectMizolastineen
dc.titleReversible anti-settlement activity against Amphibalanus (= Balanus ) amphitrite, Bugula neritina , and Hydroides elegans by a nontoxic pharmaceutical compound, mizolastineen
dc.typeArticleen
dc.identifier.journalBiofoulingen
dc.contributor.institutionYangzhou University, Yangzhou, Chinaen
dc.contributor.institutionHong Kong University of Science and Technology, Hong Kong, Chinaen
kaust.grant.numberKAUST005-CML.07/08en
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.